Pawel Muranski
YOU?
Author Swipe
View article: Fludarabine pharmacokinetics and dynamic immune monitoring as predictive biomarkers for CD19 and BCMA CAR-T
Fludarabine pharmacokinetics and dynamic immune monitoring as predictive biomarkers for CD19 and BCMA CAR-T Open
Introduction: The optimal use of fludarabine-based lymphodepletion (LD) and the requisite degree of lymphopenia for chimeric antigen receptor (CAR) T-cell efficacy and toxicity are not well-defined across different targets. We analyzed the…
View article: The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses
The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses Open
T cell immunity plays a central role in clinical outcomes of Coronavirus Infectious Disease 2019 (COVID-19) and T cell-focused vaccination or cellular immunotherapy might provide enhanced protection for some immunocompromised patients. Pre…
View article: Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient
Case Report: Kinetics and durability of humoral and cellular response of SARS-CoV-2 messenger RNA vaccine in a lung and kidney transplant recipient Open
We present a case report of a 63-year-old female health care worker who is 15 years status post double lung transplant and six years status post living related donor kidney transplant who is healthy on a chronic immunosuppression regimen i…
View article: Supplementary Figure 2 from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Supplementary Figure 2 from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice Open
PDF file - 57K
View article: Supplementary Figure 1 from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Supplementary Figure 1 from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice Open
PDF file - 51K
View article: Supplementary Figure 1 from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Supplementary Figure 1 from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice Open
PDF file - 51K
View article: Data from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Data from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice Open
Purpose: Adoptive cell transfer (ACT) of tumor infiltrating or genetically engineered T cells can cause durable responses in patients with metastatic cancer. Multiple clinically modifiable parameters can comprise this therapy, including ce…
View article: Supplementary Figure 2 from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Supplementary Figure 2 from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice Open
PDF file - 57K
View article: Data from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
Data from Determinants of Successful CD8<sup>+</sup> T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice Open
Purpose: Adoptive cell transfer (ACT) of tumor infiltrating or genetically engineered T cells can cause durable responses in patients with metastatic cancer. Multiple clinically modifiable parameters can comprise this therapy, including ce…
View article: Supplemental Figure S5 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Supplemental Figure S5 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics Open
Supplemental Figure S5. Akti-treated murine CD8+ T cells have enhanced expression of "naïve/memory"-associated genes (e.g. Klf2, Tcf7, Lef1, Foxo1, and Sell) and decreased expression of "effector"-associated genes (e.g. Eomes, Prf1, GzmB, …
View article: Data from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Data from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts Open
T-cell–based immunotherapies can be effective in the treatment of large vascularized tumors, but they rely on adoptive transfer of substantial numbers (∼20 million) of tumor-specific T cells administered together with vaccination and high-…
View article: Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts Open
Supplementary Figure 5 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
View article: Supplemental Figure S2 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Supplemental Figure S2 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics Open
Supplemental Figure S2. CD8+ tumor-infiltrating lymhphocytes (TIL) isolated from patient with melanoma have reduced phosphorylation of Akt T308 and GSK3βS9 in presence of Akt inhibitor.
View article: Supplemental Figure S3 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Supplemental Figure S3 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics Open
Supplemental Figure S3. Surface phenotype of Akti-treated and vehicle TIL isolated from patient with melanoma and expanded to clinical scale for 30 days prior to adoptive-transfer into humanized mouse model.
View article: Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts Open
Supplementary Figure 2 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
View article: Supplementary Figure 3 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 3 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts Open
Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
View article: Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts Open
Supplementary Figure 2 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
View article: Supplementary Figure 3 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 3 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts Open
Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
View article: Data from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Data from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics Open
Adoptive cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TIL) results in complete regression of advanced cancer in some patients, but the efficacy of this potentially curative therapy may be limited by poor persistence …
View article: Supplemental Figure S4 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Supplemental Figure S4 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics Open
Supplemental Figure S4. Akti-treated tumor-specific Pmel CD8+ T cell have reduced phosphorylation of Akt and substrates in presence of pharmacologic inhibition of Akt.
View article: Supplemental Figure S3 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Supplemental Figure S3 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics Open
Supplemental Figure S3. Surface phenotype of Akti-treated and vehicle TIL isolated from patient with melanoma and expanded to clinical scale for 30 days prior to adoptive-transfer into humanized mouse model.
View article: Supplemental Figure S7 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Supplemental Figure S7 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics Open
Supplemental Figure S7. Pharmacologic inhibition of Akt modulates global metabolic profile and key lipid metabolites of antigen-experienced murine CD8+ T cells.
View article: Supplementary Figure 4 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 4 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts Open
Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
View article: Supplemental Figure S1 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Supplemental Figure S1 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics Open
Supplemental Figure S1. Clinical strategy to pharmacologically inhibit Akt during ex vivo expansion of tumor-infiltrating lymphocytes (TIL).
View article: Supplemental Figure Legend from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Supplemental Figure Legend from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics Open
Supplemental Figure Legend. Legend for Supplemental Figures S1-S7.
View article: Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts Open
Supplementary Figure 5 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts